Do you want to read an article? Please log in or register.
Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2
Myeloproliferative Neoplasms (MPNs)
